Navigation Links
Watson Files FDA Application for Generic YAZ(R)

- Paragraph IV Patent Challenge Underway -

CORONA, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of YAZ(R) tablets prior to the expiration of patents owned by Bayer Schering Pharma AG and Bayer Healthcare Pharmaceuticals Inc. (Bayer). Bayer filed suit against Watson on November 5, 2007 in the U.S. District Court, District of Nevada, seeking to prevent Watson from commercializing its product prior to the expiration of patents numbered 6,787,531, RE 37,564 and RE 37,838. Bayer's suit was filed under the provisions of the Hatch Waxman Act, resulting in a stay of FDA approval of Watson's ANDA for 30 months or until final resolution of the matter before the court, whichever occurs sooner.

YAZ(R) (drosperinone and ethinyl estradiol tablets) is indicated for the prevention of pregnancy.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

YAZ(R) is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.


SOURCE Watson Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Alvarado Hospital Files Countersuit Against Blue Shield
5. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
6. Pharsight Files Application for Nasdaq Capital Market Listing
7. Gentiva(R) Health Services Files Universal Shelf Registration Statement
8. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
9. CIGNA Behavioral Health Offers Members Online Provider Profiles
10. American Media Operations, Inc. Files Form 10-Q For First Quarter 2007
11. RxElite Files Registration Statement with Securities and Exchange Commission
Post Your Comments:
(Date:11/30/2015)... MN (PRWEB) , ... December 01, 2015 , ... ... is the latest carrier to offer individual vision insurance plans on ... the unique ability to rate and review products, allowing consumers to compare, quote ...
(Date:11/30/2015)... ... 2015 , ... During the National Family Caregivers Month, the ... webinars on topics of ‘Medical and Palliative Care Decisions,’ and ‘Self-Care for Caregivers.’ ... , With a loved one's diagnosis of mesothelioma, the closest family member is ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... surgery and dermatology, is proud to announce that its ThermiRFR temperature controlled radiofrequency ... ThermiRF is an innovative multi-application radiofrequency platform which uses temperature as a clinical ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... this summer, ushering in a new era of publicly accessible automated technology. Now, ... will continue to offer guests an up-close look at the shuttle at MOSI’s ...
(Date:11/30/2015)... ... 30, 2015 , ... On Saturday, October 24th, 2015, at the Mill Race ... event, a 5K walk known as “Making Strides Against Breast Cancer”. Patients and staff ... also located in Battle Creek, joined in for this campaign that sought to raise ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Calif. , Nov. 30, 2015 /PRNewswire/ ... today that Matt Hogan , Chief ... Oppenheimer Healthcare Conference on Tuesday, December 8 ... is being held at the Westin Grand ... also be available for one-on-one meetings at ...
(Date:11/30/2015)... , Nov. 30, 2015 Next week, December ... of Things (DoT ) co-located events covering the latest ... Internet of Things, will draw more than 3,000 design ... Convention Center. The events, combined show floor will ... --> --> ...
(Date:11/30/2015)... Nautilus Medical Inc. today announced worldwide availability of MatrixRay, ... The release of MatrixRay to the entire medical healthcare ... America) in Chicago - the ... --> --> MatrixRay is the first ... worldwide via a peer-to-peer exchange network of physicians and ...
Breaking Medicine Technology: